Verona begins PK trial for RPL554 in healthy volunteers

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) began a 2-way crossover, U.S. trial

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE